🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesArterial stiffness reduction on GLP-1 — July 2024 Page 6

Arterial stiffness reduction on GLP-1 — July 2024

pat_auckland Wed, Feb 7, 2024 at 4:47 PM 47 replies 2,796 viewsPage 6 of 10
sarah_nash92
Member
712
3,123
Jun 2024
Nashville, TN
Apr 30, 2024 at 9:01 AM#26

Following on from anna.melb_AU — and this may be the naive question:

Was that from a primary source or from a summary of one?

Last edited: Apr 30, 2024 at 3:01 PM
26 24NauseaFreeNow, SteveThurs, B12Beth and 23 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
May 11, 2024 at 8:43 AM#27
dave_SLC said:
anna.melb_AU said: ...cardiovascular risk is just another fad...

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

References:
[1] Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.
27 0NauseaFreeNow, SteveThurs, B12Beth and 24 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
May 22, 2024 at 8:18 AM#28
dave_SLC said:
anna.melb_AU said: ...cardiovascular risk is just another fad...

I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

11 months later: down 48 lbs, off metoprolol, A1C from 7.6% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

28 1HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 25 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
ricardo_MIA
Member
378
1,678
Sep 2024
Miami, FL
Jun 2, 2024 at 7:47 AM#29
dave_SLC said:
anna.melb_AU said: ...cardiovascular risk is just another fad...

Thank you for spelling out the reasoning rather than just the conclusion. I will report back once I have actually tried it.

29 2KetoKyle, CanadaChris, ZaraB_AL and 26 others
Reply Quote Save Share Report
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Jun 13, 2024 at 7:09 AM#30
Dr.MetabolicMD said:
I'm 58 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

Last edited: Jun 13, 2024 at 11:09 AM
1 24dan_philly
Reply Quote Save Share Report
14567810

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register